GlassScriptPhysician profile
Pranith Surabhi
NPI 1891074803
$6,598.24
in general payments reported to CMS, 2019-2025
42 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $838 · 2021: $1,133 · 2022: $741 · 2023: $1,205 · 2024: $852 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.59 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $984.66 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $770.16 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $589.20 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $537.40 | 2019-2025 | |
| Lilly USA, LLC | $468.76 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $457.88 | 2020-2025 | Camzyos |
| Abbvie INC. | $365.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $205.71 | 2020-2025 | Invega Sustenna, Spravato |
| Boston Scientific Corporation | $187.71 | 2023 | |
| Sanofi-Aventis U.S. LLC | $157.77 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $151.20 | 2022 | |
| Abbott Laboratories | $126.64 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $125.00 | 2025 | Cobalt Dr Mri Surescan |
| Sumitomo Pharma America, INC. | $124.90 | 2023 | Gemtesa |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.95 | 2019-2024 | Xifaxan |
| Mylan Specialty L.P. | $107.58 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $105.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $103.11 | 2020-2024 | Gardasil 9, Rotateq, Capvaxive |
| Esperion Therapeutics, INC. | $95.51 | 2020-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $82.37 | 2022-2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $55.32 | 2023-2024 | Uptravi, Opsumit |
| Janssen Biotech, INC. | $47.39 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $46.93 | 2020-2021 | |
| Incyte Corporation | $46.18 | 2024 | Opzelura |
| Astellas Pharma US INC | $32.29 | 2024-2025 | Veozah |
| Lundbeck LLC | $32.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.28 | 2022 | |
| Glaxosmithkline, LLC. | $30.22 | 2020-2023 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $21.98 | 2023 | Gvoke Hypopen |
| Ucb, INC. | $20.25 | 2024 | Bimzelx |
| Ultragenyx Pharmaceutical INC. | $16.01 | 2022 | |
| Grifols USA, LLC | $15.70 | 2023 | Prolastin-C Liquid |
| Dexcom, INC. | $15.25 | 2023 | Dexcom G6 Transmitter |
| Organon LLC | $14.86 | 2023 | |
| Exact Sciences Corporation | $14.47 | 2025 | The Cologuard Plus Collection Kit |
| Eisai INC. | $14.33 | 2020 | |
| Corcept Therapeutics | $13.80 | 2024 | Korlym |
| Genentech USA, INC. | $13.35 | 2021 | |
| Amarin Pharma, INC. | $13.32 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.69 | 2025 | Voquezna |
| Allergan, INC. | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranith Surabhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.